JACC Cardiovasc Imaging
July 2024
In at least one-half of the patients with angina or ischemia and nonobstructive coronary arteries undergoing coronary function testing, coronary artery spasm (CAS) is detected. CAS is associated with an adverse prognosis regarding recurrent complaints and ischemic events. Current treatment options are mainly focused on the complaints, not on the underlying pathophysiological process.
View Article and Find Full Text PDFPrediction of bleeding risk in patients receiving antithrombotic treatment has been repeatedly attempted and resulted in multiple risk models. Risk stratification can be used to personalize antithrombotic treatment to reduce bleeding complications. Although these risk models are validated and incorporated in the current guidelines, the feasibility and effectivity in daily practice remains questionable.
View Article and Find Full Text PDFBackground: P2Y12 inhibitor monotherapy is a promising novel strategy to reduce bleeding complications compared to dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI). In order to personalise treatment with DAPT based on patients' bleeding risk, we compared outcomes after PCI between P2Y12 inhibitor monotherapy and DAPT according to bleeding risk.
Methods: A search for randomized clinical trials (RCTs) comparing P2Y12 inhibitor monotherapy after a short period of DAPT to standard DAPT after PCI was performed.